ArticleInternational journal of cardiology. Heart & vasculature2026
Role of (pro) renin receptor in adriamycin-induced cardiomyopathy.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: (Pro) renin receptor (PRR) is a newly recognized element of the renin-angiotensin system associated with cardiovascular diseases. Nevertheless, the exact roles of PRR in adriamycin-induced cardiomyopathy (ADR-CM), represented as decreased heart function or symptoms or signs of heart failure, remain incompletely understood. Methods: A rat model of ADR-CM was established by intraperitoneally injecting adriamycin (ADR). Primary neonatal rat cardiomyocytes (NRCMs) and cardiac fibroblasts (NRCFs) were stimulated with ADR. PRR inhibitor PRO20 was synthesized and utilized to assess its effects on ADR-CM rats. PRR gene overexpression and silencing were achieved through transfecting recombinant adenoviruses containing PRR and PRR-shRNA in rats and cells. The ERK inhibitor PD98059 was used to suppress phosphorylated ERK1/2 (pERK1/2) in cells. Results: PRR was significantly upregulated in ADR-CM and ADR-stimulated NRCMs and NRCFs. In vivo experiments demonstrated that PRR overexpression exacerbated ADR-induced cardiac dysfunction and myocardial hypertrophy, while systemic administration of PRO20 attenuated ADR-induced this effect. In vivo and vitro experiments, systemic PRO20 administration and PRR gene knockdown attenuated ADR-induced fibrosis, inflammatory response, apoptosis and oxidative stress, whereas PRR overexpression had the opposite effects. Inhibition of PRR decreased ADR-induced cardiac renin activity, angiotensin II (Ang II) concentration and pERK1/2 protein level, while overexpression of PRR increased these indices in the presence of ADR. PD98059 attenuated cardiomyocyte fibrosis, inflammatory response, apoptosis, and reduced NOX2 abundance and NOX activity in ADR-treated NRCFs. Conclusion: PRR is involved in the pathological progression of ADR-CM, and inhibition of PRR may represent a novel and promising therapeutic strategy for ADR-CM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.